Lv5
810 积分 2025-08-04 加入
A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
1个月前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
3个月前
已完结
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
4个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of HRS ‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
4个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
5个月前
已完结
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
5个月前
已关闭
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
6个月前
已完结
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
6个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
9个月前
已完结
2023 International Rome consensus for the nomenclature of Sjögren disease
10个月前
已完结
皖公网安备34019202002308
